Tackling the Diversity of Triple-Negative Breast Cancer
- 1 December 2013
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (23), 6380-6388
- https://doi.org/10.1158/1078-0432.ccr-13-0915
Abstract
Triple-negative breast cancer (TNBC) comprises a highly diverse collection of cancers. Here, we review this diversity both in terms of gene expression subtypes and the repertoire of genetic events. Transcriptomic analyses of TNBC have revealed at least six subtypes, with the luminal androgen receptor (luminal AR) or molecular apocrine cancers forming a distinct group within triple-negative disease. Distinct from the gene expression subtypes, a diverse set of genetic events have been described in TNBC, with a number of potentially targetable genetic events found although all at relatively low frequency. Clinical trials to define the clinical utility of therapies targeting these low-frequency events will require substantial screening efforts to identify sufficient patients. Set against the diversity of TNBC, clinical studies of patients with triple-negative disease will need to be either focused on molecularly defined subsets with upfront molecular stratification, or powered for a secondary endpoint analysis of a molecularly defined subset. Such approaches will be crucial to realize the potential of precision medicine for patients with TNBCs.Keywords
This publication has 69 references indexed in Scilit:
- Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15Breast Cancer Research, 2013
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the OutcomeClinical Breast Cancer, 2013
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The Life History of 21 Breast CancersCell, 2012
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrumLaboratory Investigation, 2009
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaLaboratory Investigation, 2005